Humanigen

HGEN

ATLANTA, GA – – (Newsfile Corp. – September 22, 2022) – – Holzer & Holzer, LLC informs investors that a class action lawsuit was filed against Humanigen, Inc. (“Humanigen” or the “Company”) (NASDAQ: HGEN).  The lawsuit alleges Humanigen made materially false and misleading statements and/or failed to disclose that: (1) its product, lenzilumab, was less effective in treating hospitalized COVID-19 patients than the Company had represented; (2) as a result, the FDA was unlikely to approve an emergency use authorization for lenzilumab and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (3) accordingly, lenzilumab’s clinical and commercial prospects were overstated.

 

If you bought shares of Humanigen between May 28, 2021 to July 12, 2022, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/humanigen/ to learn more.

 

The deadline to ask the court to be appointed lead plaintiff in the case is October 25, 2022.

Registration Deadline

Lead Plaintiff Deadline Has Passed

October 25, 2022

Submit Your Information

Name
Address
Shares Purchased
Date Puchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date Sold
Number of Shares Sold
Selling Price Per Share
 
By clicking on the button below, I am requesting Holzer & Holzer, LLC send me documents necessary to retain the firm.